3 top pharma stocks immune to Brexit: AstraZeneca plc, Shire plc and Hikma Pharmaceuticals plc

Bilaal Mohamed looks at three pharmaceuticals plays that could offer shelter from Brexit panic: AstraZeneca plc (LON: AZN), Shire plc (LON: SHP) and Hikma Pharmaceuticals plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’ll be discussing the outlook for FTSE 100 pharmaceutical giants AstraZeneca, Shire and Hikma Pharmaceuticals. Shares in all three companies have outperformed the market since the vote to leave the EU, but are they likely to be sound investments in the longer term?

Brexit-resistant drugmaker

Anglo-Swedish drugs giant AstraZeneca (LSE: AZN) has won approval for a new antibiotic in the fight against drug resistance. The company was granted marketing authorisation by the European Commission for its Zavicefta treatment, a combination antibiotic developed in response to the increasingly urgent need for new drugs to treat serious infections that are becoming increasingly resistant to antibiotics.

Shares in the FTSE 100 stalwart have rallied over the past week or so, with impressive gains since the UK’s decision to leave the EU. But the market is expecting Astra to report a 14% dip in earnings for the full year to £3.4bn on significantly lower revenues, and I believe the shares look expensive at 17 times earnings. However, attractions remain for income-seekers with dividend payouts yielding well over 4% and covered almost one-and-a-half times by forecast earnings.

Unexpected boost

Dublin-based pharmaceuticals firm Shire (LSE: SHP) received an unexpected boost recently when a drug that had failed tests to treat a form of infant blindness instead showed positive effects on severe complications relating to lung and brain damage. The company hopes to start discussions with regulators about a phase-three clinical programme focusing on clinically relevant complications of prematurity later this year.

Like its larger rival AstraZeneca, Shire has outperformed the rest of the index since the vote to leave the EU, as investors have flocked to defensive sectors like pharmaceuticals and utilities. Analysts are talking about an impressive 77% rise in earnings this year, followed by a further 17% next year, leaving the shares trading on a reasonable P/E rating of 14 for 2017. I believe the shares still offer good value given the strong growth outlook.

Back to the big league

A welcome back to the FTSE 100 for Hikma Pharmaceuticals (LSE: HIK), which re-joined the top index recently after being relegated to the FTSE 250 in March following a share price slump at the start of the year. The drugmaker received a further boost recently after winning a court case dismissing claims of a patent infringement involving a rival’s gout treatment.

The son of the firm’s founder and current chief executive Said Darwazah celebrated the court case win by purchasing 150,000 shares worth £3.3m, along with two other directors who also bought 150,000 shares on the same day. Hikma’s shares have gained 21% in just three months and look to be trading at a premium 30 times forecast earnings for the year to December. I would put the stock on my watch list and wait for a better entry point before dipping into this quality pharmaceuticals play.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »